Spotlight On: Lantus® / Lantus® SoloSTAR® (Insulin Glargine Recombinant) / Basaglar® (Insulin Glargine) / Semglee® (Insulin Glargine) / Rezvoglar™ (Insulin Glargine-Aglr) - May 2026

Why It Matters

Patent challenges could weaken exclusivity for Lantus and its biosimilars, potentially lowering prices and altering market share in the U.S. diabetes‑care sector.

Key Takeaways

• Multiple insulin glargine patents face IPR and court challenges.
• Claim counts may be duplicated across separate proceedings.
• Litigation focuses on Lantus and its biosimilars.
• Patent outcomes could reshape U.S. diabetes drug market.

Pulse Analysis

The insulin glargine franchise, anchored by Sanofi’s Lantus® and extended through biosimilars like Basaglar®, Semglee® and Rezvoglar™, has long enjoyed robust patent protection. Recent Inter Partes Review (IPR) filings and federal lawsuits, however, signal a coordinated effort by generic manufacturers and challenger firms to erode that shield. By contesting claims under both §§ 102 and 103, petitioners aim to invalidate the foundational inventions that grant market exclusivity, a strategy that has succeeded in other biologic arenas and could set a precedent for future biosimilar roll‑outs.

Counting methodology matters because a single claim may be tallied in multiple forums, inflating the perceived volume of contested intellectual property. This duplication underscores the intensity of the legal battle: each patent claim is a potential lever to unlock market entry for lower‑cost alternatives. For investors and industry analysts, the cumulative claim count offers a proxy for the risk exposure of the glargine portfolio, informing valuation models for both the patent holder and prospective entrants.

If the IPRs and litigations succeed in invalidating key claims, the immediate impact would be a reduction in royalty streams and a possible price decline for long‑acting insulin. More broadly, a weakened patent fence could accelerate biosimilar adoption, reshaping prescribing patterns and reimbursement negotiations across the U.S. healthcare system. Stakeholders should monitor upcoming USPTO decisions and court rulings, as they will likely dictate the competitive dynamics of the diabetes market for the next decade.